T2 Biosystems' Q4 Loss Increases on Higher Expenses | GenomeWeb

NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market Tuesday that its fourth quarter and full-year 2014 loss increased as it ramped up R&D and invested in clinical trials for its T2Candida Panel and T2Dx instrument.

The Lexington, Mass.-based molecular diagnostics firm reported research and grant revenues for the quarter of $119,000, up from $55,000 in the fourth quarter of 2013. It didn't report any commercial revenues in the quarter or full year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.